カワムラ　ヒデマサ   KAWAMURA Hidemasa   河村　英将    所属   埼玉医科大学  医学部 総合医療センター　放射線科(画像診断・核医学科、放射線腫瘍科)    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読なし
表題	Efficacy of immune checkpoint inhibitor treatment for head and neck mucosal melanoma recurrence in patients treated with carbon-ion radiotherapy.
掲載誌名	正式名：Cancer reports (Hoboken, N.J.)
掲載区分	国外
巻・号・頁	6(7),e1825頁
著者・共著者	Atsushi Musha,Nobuteru Kubo,Hidemasa Kawamura,Naoko Okano,Hiro Sato,Kohei Okada,Kento Tomizawa,Norichika Ota,Akiko Adachi,Masato Shino,Osamu Nikkuni,Shota Ida,Katsuyuki Shirai,Jun-Ichi Saitoh,Satoshi Yokoo,Kazuaki Chikamatsu,Tatsuya Ohno
発行年月	2023/04/28
概要	BACKGROUND: Carbon-ion radiotherapy (C-ion RT) is effective for head and neck mucosal melanoma (HN-MM), including radioresistant mucosal melanoma. Melanoma also responds effectively to immune checkpoint inhibitors (ICIs). Data on the efficacy and safety of ICIs for HN-MM are insufficient. AIMS: To analyze the efficacy and safety of ICI salvage therapy in patients with HN-MM recurrence after C-ion RT. METHODS AND RESULTS: This retrospective study analyzed the medical records of 52 patients with HN-MM treated with C-ion RT between 2012 and 2020. A dose of 57.6 or 64.0 Gy (relative biological effectiveness) was provided in 16 fractions. The primary endpoint was 3-year overall survival (OS) rate. The median follow-up time was 26.8 months for all patients. A total of 29 patients had local recurrence or distant metastasis, and 16 patients who received ICI therapy. The 3-year OS rate in the ICI group (n = 16) and best supportive care group (n = 13) were 53.8% and 0.0%, respectively (p = 0.837); the difference was not statistically significant. There were no deaths after 1 year among patients who underwent ICI therapy. No adverse events associated with C-ion RT were related to or exacerbated by ICI. CONCLUSION: ICI salvage therapy is effective and safe for patients with HN-MM recurrence after C-ion RT.
DOI	10.1002/cnr2.1825
PMID	37115713